Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, ...

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

The U.S. Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) for the treatment of the blood and bone cancers known as chronic lymphocytic leukemia (CLL) and small lymphocytic ...

BEIJING--(BUSINESS WIRE)--American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic ...

Credit: Bristol Myers Squibb. The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, which included adults with relapsed or refractory CLL or SLL after progression on a BTKi and ...

Eli Lilly (NYSE:LLY) reported positive Phase 3 data from its BRUIN CLL-321 study of its drug pirtobrutunib, also known as Jaypirca, in the treatment adult patients with chronic lymphocytic leukemia, ...

Key opinion leaders open a discussion surrounding CLL and SLL, and describing unique characteristics of each disease state. This is a video synopsis/summary of a Peer Exchange involving Ryan ...

Bristol Myers Squibb (NYSE:BMY) said the FDA has accepted its application to have its CART T cell therapy Breyanzi approved for the treatment of certain patients with chronic lymphocytic leukemia, or ...

At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December updated results from the global, multi-centre, open-label, Phase III BRUIN CLL-313 clinical trial were presented. This ...

The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...